Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance

doi:10.1038/srep25468

	Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance
	Wang, Yuetong 1,2,3; Huang, Hsin-Yi 1,2,3; Yang, Liu 1,2,3; Zhang, Zhanxia 1,2,3; Ji, Hongbin1,2,3,4
	2016-05-06
发表期刊	SCIENTIFIC REPORTS (IF:3.8[JCR-2023],4.3[5-Year])
ISSN	2045-2322
卷号	6
发表状态	已发表
DOI	10.1038/srep25468
摘要	Drug resistance to tyrosine kinase inhibitor (TKI) is the main obstacle for efficient treatment of epidermal growth factor receptor (EGFR)-mutant lung cancer patients. Here we design a cetuximab-capped mesoporous silica nanoparticle (MP-SiO2 NP) as the drug carrier to specifically target EGFRmutant lung cancer cells and efficiently release loaded drugs including doxorubicin and gefitinib. This innovative nano-medicine can specifically target lung cancer cells with high EGFR expression rather than those with low EGFR level. Treatment of a gefitinib-resistant cell line derived from PC9 cell (PC9-DR) with the gefitinib-loaded cetuximab-capped MP-SiO2 NP showed a significant inhibition of cell growth. Moreover, this nano-medicine successfully suppressed the progression of PC9-DR xenograft tumors. This tumor suppression was due to the endocytosis of large amount of nano-medicine and the effective gefitinib release induced by high glutathione (GSH) level in PC9-DR cells. Collectively, our study provides a novel approach to overcome EGFR-TKI resistance using cetuximab modified MP-SiO2 NP, which holds strong potential for effective management of EGFR-mutant lung cancer.
收录类别	SCI
语种	英语
资助项目	Shanghai Institutes for Biological Sciences[2014KIP304]
WOS研究方向	Science & Technology - Other Topics
WOS类目	Multidisciplinary Sciences
WOS记录号	WOS:000375427700001
出版者	NATURE PUBLISHING GROUP
WOS关键词	IN-VIVO ; ANTICANCER DRUG ; DELIVERY ; NANOPARTICLES ; RELEASE ; MUTATIONS ; INHIBITORS ; STIMULI ; NANOCONTAINERS ; GATEKEEPERS
原始文献类型	Article
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/1840
专题	生命科学与技术学院_特聘教授组_季红斌组
通讯作者	Zhang, Zhanxia; Ji, Hongbin
作者单位	1.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Syst Biol, Shanghai 200031, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai 200031, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Innovat Ctr Cell Signaling Network, Shanghai 200031, Peoples R China 4.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 200120, Peoples R China
通讯作者单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Wang, Yuetong,Huang, Hsin-Yi,Yang, Liu,et al. Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance[J]. SCIENTIFIC REPORTS,2016,6.
APA	Wang, Yuetong,Huang, Hsin-Yi,Yang, Liu,Zhang, Zhanxia,&Ji, Hongbin.(2016).Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance.SCIENTIFIC REPORTS,6.
MLA	Wang, Yuetong,et al."Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance".SCIENTIFIC REPORTS 6(2016).